fedratinib: Clinical Trials

3 trials of fedratinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 2, Completed 1

Follow fedratinib: new trials by email Literature Review of fedratinib trials Research Report on fedratinib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
FEDRATINIB, Best Available Therapy (BAT) - Primary Myelofibrosis, Post-Polycythemia Vera
Phase 3CompletedCelgene2022019-09-092025-08-28
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
FEDRATINIB - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Phase 3TerminatedCelgene382019-03-272024-12-12
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis
SAR302503, Placebo - Hematopoietic Neoplasm
Phase 3TerminatedBristol-Myers Squibb2892011-12-312026-08-11

Conditions studied

Myeloproliferative Disorders (2)  ·  Primary Myelofibrosis (2)  ·  Hematologic Neoplasms (1)

Sponsors

Celgene (2)  ·  Bristol-Myers Squibb (1)

Countries

Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  Ireland (2)  ·  Italy (2)  ·  Poland (2)  ·  Russia (2)  ·  South Korea (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)

Results publications

PMID 26181658, PMID 38838026, PMID 39265613

NIH funding

2018 (2)